Clik here to view.
Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3...
ALAMEDA, Calif. Exelixis, Inc. (Nasdaq: EXEL) announced today that its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has reported positive results from a phase 3 pivotal trial of...
View ArticleClik here to view.
New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo)...
View ArticleClik here to view.
武田薬品とMDアンダーソンが臨床試験段階の既製品用CAR NK細胞療法薬プラットフォーム開発を加速するための提携を発表
ヒューストン & 大阪 （ビジネスワイヤ） — テキサス大学MDアンダーソンがんセンターと武田薬品工業株式会社（TSE:4502/NYSE:TAK）（以下、武田薬品）は本日、B細胞性悪性腫瘍やその他のがんの治療に向け、IL-15分泌を促進するとともにキメラ抗原受容体を発現した臍帯血由来ナチュラルキラー（CAR...
View ArticleClik here to view.
Promega与默克达成全球合作，开发可搭配可瑞达®使用的微卫星不稳定(MSI)伴侣诊断试剂
威斯康星州麦迪逊 (美国商业资讯)–Promega Corporation今天宣布与默克（Merck，美国和加拿大以外称为默沙东）达成一项全球合作，开发Promega的微卫星不稳定(MSI)技术作为一种载入说明书的实体瘤伴侣诊断试剂(CDx)，与默克的抗PD-1治疗药物可瑞达®（KEYTRUDA®，帕博利珠单抗）搭配使用。此次全球合作的初期将寻求美国和中国监管部门核准Promega MSI...
View ArticleClik here to view.
Ningbo Tai Kang Medical Technology Co., Ltd Announces Global Licensing...
NINGBO, China Ningbo Tai Kang Medical Technology Co. Ltd. announced today that it has entered into a licensing agreement with AstraZeneca. Tai Kang has been granted the exclusive global rights to...
View ArticleClik here to view.
prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized,...
SEOUL, South Korea prismCDX, a highly specialized contract research organization announced today the selection and adoption of the UltiMapper platform to broaden its offering of translational...
View ArticleClik here to view.
Clik here to view.
幹細胞移植歴のない多発性骨髄腫患者を対象としたファーストライン維持療法としてのニンラーロ（イキサゾミブ）の第3相試験で主要評価項目を達成
米マサチューセッツ州ケンブリッジ & 大阪 ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502/NYSE:...
View ArticleClik here to view.
NINLAROTM (ixazomib)作为未接受干细胞移植的多发性骨髓瘤患者一线维持治疗的3期试验达到主要终点
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE: TAK)（“武田”）今天宣布，随机、3期TOURMALINE-MM4研究达到主要终点无进展生存(PFS)。该试验比较单药口服NINLARO™...
View ArticleClik here to view.
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen...
TOKYO & BASEL, Switzerland & MANNHEIM, Germany NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on...
View ArticleClik here to view.
Mevion Signs Agreement to Develop Proton Center in Tianjin, China
LITTLETON, Mass. Mevion Medical Systems has signed an agreement with Tianjin Port Free Trade Zone Administrative Committee and Tianyi Holdings to develop a proton therapy center in the rapidly...
View ArticleClik here to view.
注意-更正并替换：Promega与Merck达成全球合作共同研发针对Keytruda®的微卫星不稳定性(MSI)检测伴随诊断试剂
美国威斯康星州麦迪逊市 (美国商业资讯) Promega(普洛麦格)与Merck(美国和加拿大以外称为MSD默沙东)达成一项全球合作，共同开发Promega的微卫星不稳定性(MSI)检测产品作为说明书中标注的与 Merck的抗PD-1治疗药物Keytruda®...
View ArticleClik here to view.
NEC和VAXIMM宣布合作推进个体化新抗原癌症疫苗
东京和瑞士巴塞尔和德国曼海姆 (美国商业资讯)–IT和网络技术领导者NEC Corporation (NEC; TOKYO: 6701)和专注于开发口服T细胞免疫治疗药物的瑞士/德国生物技术公司VAXIMM AG今天宣布，两家公司已签署临床试验战略合作协议和股权投资协议，以开发新型个体化新抗原癌症疫苗。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
武田将在美国血液学会(ASH)第61届年会上重点介绍扩大后的肿瘤和血液产品阵容
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502/NYSE:TAK)今天宣布将在2019年12月7-10日佛罗里达州奥兰多召开的美国血液学会第61届年会上呈报总计29篇公司赞助的摘要，凸显公司对促进血癌和出血障碍治疗的承诺。 追求肿瘤学和出血障碍领域的突破、患者为中心的创新...
View ArticleClik here to view.
Deciphera Pharmaceuticals, Inc. to Present Data from DCC-3014 and Ripretinib...
WALTHAM, Mass. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced preliminary data from the ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including initial data in...
View ArticleClik here to view.
武田薬品が第61回米国血液学会（ASH）年次総会でオンコロジーおよび血液疾患の領域における拡大した製品ポートフォリオに光を当てる
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent...
PACIFIC PALISADES, Calif. Aadi Bioscience, Inc. (Aadi), a privately held clinical stage biopharmaceutical company, today released its independent radiology reviewed data from the nab-sirolimus...
View ArticleClik here to view.
Takeda Announces 12 New Molecular Entities with the Potential for 14 Launches...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host an R&D meeting today beginning at 12:30 p.m. EST in New York City to outline how its science-first,...
View ArticleClik here to view.
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179...
CAMBRIDGE, Mass. & BEIJING & DURHAM, N.C. VBI Vaccines (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
View ArticleClik here to view.
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on...
SAN DIEGO Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the presentation of interim...
View Article